Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review - sprookjes - yvandenbroek - TriplyDB

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

http://www.wikidata.org/entity/Q27023364

about

Regulation of glucose homeostasis by GLP-1 Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors Safety of dipeptidyl peptidase 4 inhibitors: a perspective review Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes Diabetic kidney disease: a report from an ADA Consensus Conference β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies Alogliptin benzoate for management of type 2 diabetes Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.Liraglutide and obesity: a review of the data so far.Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.Effect of Modified Roux-en-Y Gastric Bypass Surgery on GLP-1, GIP in Patients with Type 2 Diabetes Mellitus Comparison of different gastric bypass procedures in gastric carcinoma patients with type 2 diabetes mellitus.Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study.GLP-1 based therapeutics: simultaneously combating T2DM and obesity.Enteral supplementation with glutamine, fiber, and oligosaccharide modulates incretin and glucagon-like peptide-2 secretion Importance of Beta Cell Function for the Treatment of Type 2 Diabetes Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Update on strategies limiting iatrogenic hypoglycemia.Management of Hyperglycemia in Diabetic Kidney Disease.Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc.Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus.Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials.Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability.Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.

P2860

Q24563430-C0C1B751-8A66-4654-835D-EB856892EB7D Q24568148-1B1FD553-B224-4AB4-A1E2-94B247017F18 Q26772081-F20DBDB3-D5EB-497D-929F-206C4410EFAB Q26863262-B58D32C8-4105-428E-8107-5246A35568CD Q27004723-62D2115D-EA41-42E0-961F-399657894E61 Q27012546-D821EDBF-6FC8-49F9-80D5-778B4F381352 Q27692665-A8B9B725-16CD-4DCA-AD6B-677471C1ABD5 Q28069065-31840DEB-18FA-4723-8819-2301829A64D0 Q28077026-B0F4EC86-DB2F-4801-A513-51E6FAB8D96C Q28079849-151613FF-5506-4828-A288-66BD4A0086C5 Q28083933-70921E2A-584F-4A91-9F1D-06290A3FAD4E Q28484498-99365C70-C126-423B-8D8E-70926CF18CF5 Q30249371-32DCAE2D-CED5-4E92-A8E1-9F7001FF4781 Q30643065-BFEBEB31-8D6D-4609-A6A3-044E37546097 Q30924982-BCB21345-F59F-4580-A7DA-AC677732CB51 Q33775785-9FFA7F5A-60AC-4D84-915A-3DEA7809DE2A Q33824522-44ED27A7-4EE0-4EFC-BF7A-B7777C06C8E5 Q34259412-24BE64AF-AFE2-42E8-A024-3A542221E280 Q34484580-F60468F4-BE40-4B52-BEEC-7B200B1C5374 Q34779258-1AA5FE73-99E5-432C-94C6-35F201F006E3 Q35061423-04BE89EC-4F9A-45F6-A853-EE49FCBE13BF Q35166849-74D359D0-DD7E-4C8E-A926-E432B905C5C0 Q35192188-81364217-62E4-4A4E-B496-D211E854C905 Q35200252-C288E981-8C5C-4B23-B235-CEFD6419E68A Q35571826-C1E5B1B6-399D-4690-9E3A-EF0B4B91608D Q35667116-94A6669F-F2FA-4C65-8A82-A99FAB2A8442 Q35784245-C103AFE3-B732-484E-BC8C-0D1CC433C041 Q35881959-78AE1AA3-59C6-49BE-9003-99FB9D454A9A Q35953856-1936A1E6-69B4-484F-963C-6356BB51F592 Q36032335-606B1BC9-FBD0-4815-B7C0-40B32BB8004C Q36192977-C061E909-75DC-4275-AB4E-3AB57FF1722D Q36307279-AD93D5F4-406E-491A-AB2A-C67C4A3D8B83 Q36354599-96994C24-0DB5-4244-A8F1-12BE2D758E89 Q36354602-076CB2FC-ECDC-4C0B-9E18-2DDFB600A506 Q36355550-E9EBEC00-54C8-42D4-815E-44C72A3D6E87 Q36429742-DE5B6E49-8D15-4F77-A09F-87557AC9A8E5 Q36856980-9B086211-75BA-4D15-9A9F-267C8CEEE9B8 Q36960161-4FCA83BF-E059-4D28-A298-8F7A5CDABF43 Q36972371-D37F5AF5-B1D4-45ED-9776-1335B36763D4 Q37020758-64E3E316-FBDE-41AA-B6FB-EB7290150C45

P2860

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

http://www.wikidata.org/entity/Q27023364

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Efficacy of GLP-1 receptor ago ...... analysis and systematic review

@ast

Efficacy of GLP-1 receptor ago ...... analysis and systematic review

@en

Efficacy of GLP-1 receptor ago ...... analysis and systematic review

@nl

type

label

Efficacy of GLP-1 receptor ago ...... analysis and systematic review

@ast

Efficacy of GLP-1 receptor ago ...... analysis and systematic review

@en

Efficacy of GLP-1 receptor ago ...... analysis and systematic review

@nl

prefLabel

Efficacy of GLP-1 receptor ago ...... analysis and systematic review

@ast

Efficacy of GLP-1 receptor ago ...... analysis and systematic review

@en

Efficacy of GLP-1 receptor ago ...... analysis and systematic review

@nl

P1433

Q27023364-E7256310-DA80-4F4C-A9CD-6CDCE59E0096

P1476

Q27023364-390A9B75-0B55-4DB2-8A96-232C0D5AD9D7

P2093

Q27023364-07B45F28-6068-4BEE-94D4-2D95C48979E9

Q27023364-3E994648-8854-45F1-8D8C-F6D992DF1552

Q27023364-88992BDB-BDB7-42B2-AF57-3B58FBDDFAD8

Q27023364-9074059B-89E3-4971-A4DD-EDD4A7903BE4

Q27023364-90E39B29-D345-4CC1-8527-42952198CCF3

Q27023364-F7C38DCB-39D8-4E5D-9D16-69B0CB43103F

P304

Q27023364-9C4AD42A-AE80-4BAD-AF62-50EA011A1CE1

P31

Q27023364-399E9025-D168-4D88-A55E-F185A9CBAF53

Q27023364-C27826AA-1623-4734-BE27-ADD6A628FCF9

Q27023364-D0DD8E9D-AFA2-4D72-A31F-E8A208E59F03

P3181

Q27023364-0531DA5C-117A-424A-AD17-B9D4DEA082D9

P356

Q27023364-68FEE4BA-CAFD-43F8-8336-4FBA87CEB1B0

P407

Q27023364-214C45E0-06B7-4532-BA2E-558526CE9717

P433

Q27023364-0E3C22D8-32B2-4C49-BBA4-72533CB6B912

P478

Q27023364-F4A741B4-7E57-401F-A465-A3FE9BF5DC16

P50

Q27023364-1622EF78-56AD-43CE-B818-AC9112D8F5D0

P577

Q27023364-872BAE0A-EEC0-4F1F-A527-15006A281415

P5875

Q27023364-D406A214-EA09-494B-BE15-C175BFBC6C30

P698

Q27023364-8AEFFFBB-D7FE-48A2-8A2E-01282BE5361D

P921

Q27023364-EABDED5E-2966-46B5-AFB9-A173419C1BCC

P3181

P356

J.CLINTHERA.2012.04.013

P1433

Clinical Therapeutics

P1476

Efficacy of GLP-1 receptor ago ...... analysis and systematic review

@en

P2093

Byron J. Hoogwerf

http://www.w3.org/2001/XMLSchema#string

Jenny Han

http://www.w3.org/2001/XMLSchema#string

Mary Beth DeYoung

http://www.w3.org/2001/XMLSchema#string

Robert R. Henry

http://www.w3.org/2001/XMLSchema#string

Vanita R. Aroda

http://www.w3.org/2001/XMLSchema#string

Wenying Huang

http://www.w3.org/2001/XMLSchema#string

P304

1247-1258.e22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

1227362

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CLINTHERA.2012.04.013

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225048217

http://www.w3.org/2001/XMLSchema#string

P698

22608780

http://www.w3.org/2001/XMLSchema#string

P921